biostudies-literatureDeng ZScience and Technology Talent Support Plan of Shaanxi Provincial People's HospitalScience and Technology Development Incubation Fund of Shaanxi Provincial People's HospitalScience and Technology Development Incubation Fund of Shaanxi Provincial People's HospitalScience and Technology Talent Support Plan of Shaanxi Provincial People's Hospital456https://www.ebi.ac.uk/biostudies/studies/S-EPMC11389485biostudies-literatureUnknown29(1)Ovarian cancer is an extremely malignant gynaecological tumour with a poor patient prognosis and is often associated with chemoresistance. Thus, exploring new therapeutic approaches to improving tumour chemosensitivity is important. The expression of transcription elongation factor B polypeptide 2 (TCEB2) gene is reportedly upregulated in ovarian cancer tumour tissues with acquired resistance, but the specific mechanism involved in tumour resistance remains unclear. In this study, we found that TCEB2 was abnormally highly expressed in cisplatin-resistant tumour tissues and cells. TCEB2 silencing also inhibited the growth and glycolysis of SKOV-3/cisplatin (DDP) and A2780/DDP cells. We further incubated human umbilical vein endothelial cells (HUVECs) with culture supernatants from cisplatinEuropean journal of medical researchTCEB2/HIF1A signaling axis promotes chemoresistance in ovarian cancer cells by enhancing glycolysis and angiogenesis.PMC113894852020YXM-132021JY-33Jin WChen LDeng ZWang WLi BZhang LXia WfalseTCEB2/HIF1A signaling axis promotes chemoresistance in ovarian cancer cells by enhancing glycolysis and angiogenesis.Ovarian cancer is an extremely malignant gynaecological tumour with a poor patient prognosis and is often associated with chemoresistance. Thus, exploring new therapeutic approaches to improving tumour chemosensitivity is important. The expression of transcription elongation factor B polypeptide 2 (TCEB2) gene is reportedly upregulated in ovarian cancer tumour tissues with acquired resistance, but the specific mechanism involved in tumour resistance remains unclear. In this study, we found that TCEB2 was abnormally highly expressed in cisplatin-resistant tumour tissues and cells. TCEB2 silencing also inhibited the growth and glycolysis of SKOV-3/cisplatin (DDP) and A2780/DDP cells. We further incubated human umbilical vein endothelial cells (HUVECs) with culture supernatants from cisplatin2024-01-01T00:00:00Z2024 Sep2025-04-04T18:52:30.559Z2025-04-04T18:52:30.559ZS-EPMC113894853926191710.1186/s40001-024-02050-9